(a) one or more active agents;
(b) 10 to 90 % (w/w) of at least one pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams; and
(c) 5 to 60 % (w/w) of at least one pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer.

The solid dispersion product comprises a matrix of the pharmaceutically acceptable polymers (b) and (c), wherein the active agent(s) is/are homogeneously distributed.

The matrix formed by the polymers (b) and (c) may be a homogenous mixture of said polymers which is chemically and physically uniform throughout or consists of only one phase (as defined in thermodynamics).

Alternatively, the mixture of polymers (b) and (c) may form a phase-separated or microphase-separated multicomponent system which comprises two or more phases which are immiscible with one another. Thus, one polymer may form domains which are interspersed in the other polymer, or two polymers form a co-continuous structure, wherein the individual polymers phases are intertwined and interlocked. In those cases where the polymers form two or more phases which are not miscible with one another the active agent can be present in the graft polymer phase or the thermoplastic polymer phase or both. The concentration of the active agent present in the individual phases is determined by its distribution coefficient.

The invention further provides a method for preparing the formulation described herein, the method comprising:

(a) preparing a homogenous melt from a mixture comprising one or more active agents; 10 to 90 % (w/w) of at least one pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams; and 5 to 60 % (w/w) of at least one pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer; relative to the total weight of the mixture;
(b) heating the blend to obtain a homogeneous melt;
(cb) forcing the thus obtained melt through one or more nozzles; and
(dc) allowing the melt to solidify to obtain a solid dispersion product.

BRIEF SUMMARY OF THE FIGURES

Figure 1 shows release of ibuprofen from solid dispersion products comprising ibuprofen, Kollidon VA64 and varying percentages of Kollicoat IR.